title: Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments.
abstract: Cancer, the most devastating chronic disease affecting humankind, is treated primarily by surgery, chemotherapy, and radiation therapy. Surgery and radiotherapy are mainly used for debulking the primary tumor, while chemotherapy is the most efficient anti-metastatic treatment. To control better metastatic cancer, the host immune system should be stimulated. Yet, successful specific stimulation of the immune system against tumors was seldom achieved even in antigenic tumors. Our working hypothesis is that aggressive in situ tumor ablation can release tumor antigens and danger signals, which will enhance anti-tumor T cell responses resulting in the destruction of residual malignant cells in primary tumors and distant metastases. We developed two efficient in situ ablation treatments for solid cancer, which can be used to destroy the primary tumors and stimulate anti-tumor immune responses. The first treatment, electrochemical ablation, is applied through intratumoral electrodes, which deliver unipolar-pulsed electric currents. The second treatment, diffusing alpha-emitters radiation therapy (DaRT), is based on intratumoral (224)Ra-loaded wire(s) that release by recoil its daughter atoms. These short-lived alpha-emitting atoms spread in the tumor and spray it with lethal alpha particles. It was confirmed that these treatments effectively destroy various malignant animal and human primary solid tumors. As a consequence of such tumor ablation, tumor-derived antigenic material was released and provoked systemic T cell-dependent anti-tumor immunological reactions. These reactions conferred protection against a secondary tumor challenge and destroyed remaining malignant cells in the primary tumor as well as in distant metastases. Such anti-tumor immune responses could be further amplified by the immune adjuvant, CpG. Electrochemical ablation or DaRT together with chemotherapy and immunostimulatory agents can serve as treatment protocols for solid metastatic tumors and can be applied instead of or in combination with surgery.
authors: The Roberts-Guthman Chair in Immunopharmacology, Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, P.O. Box 39040, Tel Aviv, 69978, Israel, ykeisari@post.tau.ac.il.
authors: Yona
authors: Y
authors: Keisari
authors: Ilan
authors: I
authors: Hochman
authors: Hila
authors: H
authors: Confino
authors: Rafi
authors: R
authors: Korenstein
authors: Itzhak
authors: I
authors: Kelson
mesh_terms: D055011:Ablation Techniques / Q000379:methods*; D000512:Alpha Particles; D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry; D000970:Antineoplastic Agents / Q000737:chemistry; D004563:Electrochemistry; D006801:Humans; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000276:immunology* / Q000532:radiotherapy*; D011883:Radium / Q000737:chemistry; D013997:Time Factors
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D011883:Radium
references: Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):966-73
references: 19480976
references: Immunol Lett. 2009 Feb 21;122(2):128-30
references: 19121337
references: Anticancer Res. 2012 Dec;32(12):5315-21
references: 23225432
references: Transl Res. 2012 Jan;159(1):32-41
references: 22153808
references: Nat Rev Cancer. 2005 Apr;5(4):263-74
references: 15776005
references: Int J Cancer. 2005 Dec 10;117(5):816-24
references: 15981217
references: J Immunol. 1961 Feb;86:228-39
references: 13785862
references: Clin Exp Immunol. 2004 Dec;138(3):410-6
references: 15544616
references: Phys Med Biol. 2006 May 7;51(9):N179-86
references: 16625028
references: Nature. 2011 Dec 21;480(7378):480-9
references: 22193102
references: PLoS One. 2012;7(11):e50299
references: 23209699
references: Cancer. 2009 Apr 15;115(8):1791-801
references: 19197995
references: Phys Med Biol. 2006 Jul 7;51(13):R303-25
references: 16790910
references: Phys Med Biol. 2007 Aug 21;52(16):5025-42
references: 17671351
references: Int J Radiat Biol. 2000 Oct;76(10):1315-22
references: 11057739
references: Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):249-59
references: 21644030
references: Mutat Res. 2011 Jun 3;711(1-2):150-7
references: 21376738
references: Proc Natl Acad Sci U S A. 2011 May 17;108(20):8293-8
references: 21527720
references: Nat Rev Drug Discov. 2011 Aug 01;10(8):591-600
references: 21804596
references: Cancer Res. 1999 Jun 1;59(11):2635-43
references: 10363986
references: Clin Cancer Res. 2003 Aug 1;9(8):3190-7
references: 12912972
references: Cancer Treat Rev. 2012 Nov;38(7):854-60
references: 22226242
references: Blood. 2002 Dec 1;100(12):4108-15
references: 12393401
references: Expert Rev Vaccines. 2011 Jun;10(6):853-73
references: 21692705
references: Int J Cancer. 2008 Apr 1;122(7):1657-64
references: 18059026
references: Immunol Rev. 2005 Oct;207:166-83
references: 16181335
references: J Immunol. 2009 Apr 15;182(8):4499-506
references: 19342621
references: J Radiat Res. 2008 May;49(3):203-10
references: 18413977
references: Clin Cancer Res. 2005 Jun 15;11(12):4451-9
references: 15958630
references: Radiology. 2011 Feb;258(2):351-69
references: 21273519
references: Prostate. 2006 Nov 1;66(15):1620-30
references: 16941466